Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy acquires Biovel vaccine business

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences. The value of the deal was not disclosed.

The transaction will provide Ranbaxy with access to all of Biovel's products (including the Typhoid Vi antigen and Hib conjugate vaccines, for which Biovel has received regulatory approval for India), intellectual property and its pipeline, along with a manufacturing facility in Bangalore, India.

Ranbaxy's CEO and MD, Atul Sobti, said: "With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy."

According to Ranbaxy, the Indian vaccine market is growing at 10 per cent per annum – 1 per cent higher than the global rate. The global vaccines market is predicted to reach $34bn by 2014.

20th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics